The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain

BMC Medical Genetics

Volumn 12, Issue , 2011, Pages

  Metzger, Brigitte ^a   Chambeau, Laetitia ^a   Begon, Dominique Y ^b   Faber, Carlo ^c   Kayser, Jacques ^c   Berchem, Guy ^d   Pauly, Marc ^a   Boniver, Jacques ^b   Delvenne, Philippe ^b   Dicato, Mario ^a,d   Wenner, Thomas ^a  

^a Laboratoire de Recherche sur le Cancer et les Maladies du Sang   (Luxembourg)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c Clinique Sainte Therese Luxembourg   (Luxembourg)

^d Centre Hospitalier   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ADVANCED CANCER; ARTICLE; CATALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DNA SEQUENCE; EUROPE; EXON; GENE FREQUENCY; GENE MUTATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; PROTEIN DOMAIN; SINGLE NUCLEOTIDE POLYMORPHISM; CAUCASIAN; COLORECTAL TUMOR; GENETICS; NUCLEOTIDE SEQUENCE; PROTEIN TERTIARY STRUCTURE;

BASE SEQUENCE; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; GENE FREQUENCY; HUMANS; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 80054860008     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-12-144     Document Type: Article

References (24)

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139. 10.1056/NEJMoa040938, 15118073.
2. Spano JP, Fagard R, Soria JC, Rixe O, Khayat D, Milano G. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol 2005, 16(2):189-194. 10.1093/annonc/mdi057, 15668269.
3. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351(4):337-345. 10.1056/NEJMoa033025, 15269313.
4. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25(13):1658-1664. 10.1200/JCO.2006.08.1620, 17470858.
5. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360(14):1408-1417. 10.1056/NEJMoa0805019, 19339720.
6. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008, 19(3):508-515.
7. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007, 67(6):2643-2648. 10.1158/0008-5472.CAN-06-4158, 17363584.
8. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11(8):753-762. 10.1016/S1470-2045(10)70130-3, 20619739.
9. Spindler KL, Pallisgaard N, Lindebjerg J, Frifeldt SK, Jakobsen A. EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer. BMC Cancer 2011, 11:107. 10.1186/1471-2407-11-107, 3073939, 21439039.
10. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007, 25(22):3238-3245. 10.1200/JCO.2007.11.5956, 17664472.
11. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500. 10.1126/science.1099314, 15118125.
12. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005, 6(5):279-286. 10.1016/S1470-2045(05)70102-9, 15863375.
13. Nagahara H, Mimori K, Ohta M, Utsunomiya T, Inoue H, Barnard GF, Ohira M, Hirakawa K, Mori M. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res 2005, 11(4):1368-1371. 10.1158/1078-0432.CCR-04-1894, 15746034.
14. Yunxia Z, Jun C, Guanshan Z, Yachao L, Xueke Z, Jin L. Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer. BMC Med Genet 2010, 11:34. 2848222, 20184776.
15. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004, 351(27):2883. 10.1056/NEJM200412303512724, 15625347.
16. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97(5):339-346. 10.1093/jnci/dji055, 15741570.
17. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359(17):1757-1765. 10.1056/NEJMoa0804385, 18946061.
18. Cappuzzo F, Finocchiaro G, Rossi E, Janne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008, 19(4):717-723.
19. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007, 97(8):1139-1145. 10.1038/sj.bjc.6604009, 2360431, 17940504.
20. Personeni N, Fieuws S, Piessevaux H, De Hertogh G, De Schutter J, Biesmans B, De Roock W, Capoen A, Debiec-Rychter M, Van Laethem JL, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 2008, 14(18):5869-5876. 10.1158/1078-0432.CCR-08-0449, 18794099.
21. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004, 64(24):8919-8923. 10.1158/0008-5472.CAN-04-2818, 15604253.
22. Douglas DA, Zhong H, Ro JY, Oddoux C, Berger AD, Pincus MR, Satagopan JM, Gerald WL, Scher HI, Lee P, et al. Novel mutations of epidermal growth factor receptor in localized prostate cancer. Front Biosci 2006, 11:2518-2525. 10.2741/1986, 16720329.
23. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23(28):6829-6837. 10.1200/JCO.2005.01.0793, 15998907.
24. Willmore-Payne C, Holden JA, Layfield LJ. Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod Pathol 2006, 19(5):634-640. 10.1038/modpathol.3800552, 16547470.